Search clinical trials for: Placebo to Grazoprevir 100 mg/Elbasvir 50 mg FDC tablet

Total 306 results

Merck Sharp & Dohme LLC

Completed

An Efficacy and Safety Study of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in the Treatment of Chronic Hepatitis C Virus (HCV) Genotype (GT)1, 4, or 6 Infection in Treatment-Naïve Participants Who Are on Opiate Substitution Therapy (MK-5172-062) (C-EDGE CO-STAR)

Chronic Hepatitis C
Merck Sharp & Dohme LLC

Completed

Study of Efficacy and Safety of Grazoprevir (MK-5172)/Elbasvir (MK-8742) Combination Regimen for Treatment-Naïve Participants With Chronic Hepatitis C Virus Genotypes 1, 4, and 6 (MK-5172-060)

Chronic Hepatitis C Virus
University of Maryland, Baltimore
Merck Sharp & Dohme LLC; Cairo University

Withdrawn

Clinical Trial to eLiminate HCV-infection in Treatment-naïve, Renally Impaired EgyptiAn Patients on Renal Dialysis, With Chronic Hepatitis C Genotype 4 (CLEAR-C4)

Hepatitis C Virus Infection, Response to Therapy of

Egypt
Azienda Ospedaliera Universitaria Policlinico Paolo...

Completed

Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in G1b Treatment-Naïve, HCV-Infected Patients (EGG-18)

Chronic HCV Hepatitis

Italy
Fundacion Clinic per a la Recerca Biomédica

Unknown

Efficacy of GZR/EBR in Early Chronic Hepatitis C in HIV/HCV Co-infected Patients (EARLY-HEP-C)

Hepatitis C | HIV

Spain
University of Illinois at Chicago
Merck Sharp & Dohme LLC

Active, not recruiting

Zepatier in Patients With Substance Use

Hepatitis C | Hiv | Substance Use Disorders | Coinfection, HIV

United States
University of Dundee

Completed

A Direct obserVed therApy vs fortNightly CollEction Study for HCV Treatment - ADVANCE HCV Study (ADVANCE)

Hepatitis C

United Kingdom
Merck Sharp & Dohme LLC

Completed

An Efficacy and Safety Study of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in the Treatment of Chronic Hepatitis C Virus in Participants Who Are Co-Infected With Human Immunodeficiency Virus:C-EDGE CO-INFXN (MK-5172-061)

Chronic Hepatitis C
Oregon Health and Science University

Completed

Hepatitis C Treatment in PWIDs: MAT or Syringe Exchange Assisted-therapy vs Standard of Care

Substance Abuse, Intravenous | Hepatitis C | Substance Use Disorders

United States
Taichung Veterans General Hospital
Merck Sharp & Dohme LLC

Terminated

Grazoprevir/Elbasvir for Genotype 1b Chronic Hepatitis C After Liver or Kidney Transplantation

Liver Transplant Infection | Kidney Transplant Infection | Chronic Hepatitis c

Taiwan
Institute Of Cardiology & Internal Diseases, Kazakhstan
Merck Sharp & Dohme LLC; Synergy Research Group

Unknown

Open-Label Efficacy and Safety Study of the Elbasvir/ Grazoprevir Fixed Dose Combination Patients With Chronic HCV GT1b

Metabolic Syndrome | Fibrosis, Liver | Cirrhoses, Liver | Chronic Hepatitis C Genotype 1B

Kazakhstan
Merck Sharp & Dohme LLC

Completed

Efficacy and Safety of Combination Grazoprevir (MK-5172)/Elbasvir (MK-8742) Versus Sofosbuvir + Pegylated Interferon + Ribavirin in Hepatitis C Virus Genotype 1, 4 or 6 Infection (MK-5172-077)

Hepatitis C
Fundacion Clinic per a la Recerca Biomédica

Withdrawn

Pilot Study Evaluate Efficacy of Grazoprevir + Elbasvir for 12 or 16 Weeks in Liver Transplant Recipients. (EGRADICATE)

Liver Transplantation | Hepatitis C
University of Pennsylvania
Merck Sharp & Dohme LLC

Completed

Administration of Zepatier (Grazoprevir Plus Elbasvir) in Chronic Hemodialysis (HD) Patients With Hepatitis C (HD)

Hepatitis C | Hemodialysis | Nosocomial Infection

United States
Merck Sharp & Dohme LLC

Completed

Efficacy and Safety of Elbasvir (MK-8742) + Grazoprevir (MK-5172) in Treatment-Naïve/Treatment-Experienced (TN/TE) French Participants With Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection (MK-5172-096)

Hepatitis C Virus (HCV) Infection

France
Galapagos NV

Completed

Multiple Ascending Dose Study of GLPG0634 in Japanese and Caucasian Healthy Subjects

Healthy

United Kingdom
Sprout Pharmaceuticals, Inc

Terminated

12 Week Safety Trial of Flibanserin in Depressed Women Taking an SSRI or SNRI With Decreased Sexual Desire and Distress

Depression | Sexual Dysfunctions, Psychological

United States
Cassava Sciences, Inc.
National Institute on Aging (NIA)

Completed

PTI-125 for Mild-to-moderate Alzheimer's Disease Patients

Alzheimer Disease

United States
AstraZeneca

Completed

AZD5069 Neutrophil Function Study

Chemokine Receptor 2 (CXCR2) Antagonist

United Kingdom
HighTide Biopharma Pty Ltd

Completed

A Multiple Ascending Dose Study of HTD1801 in Adults With Hypercholesterolemia

Hypercholesterolemia

Australia
Sprout Pharmaceuticals, Inc

Completed

Flibanserin Versus Placebo in Premenopausal Women With HSDD

Sexual Dysfunctions, Psychological

Austria, Belgium, Czech Republic, Finland, France, Germany, Hungary, Italy, Netherlands, Norway, Spain, Sweden, United Kingdom
Janssen Research & Development, LLC

Completed

A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants

Healthy

United States
Guangdong Zhongsheng Pharmaceutical Co., Ltd.

Completed

Study in Chinese Healthy Adults to Evaluate the Safety, Tolerability and Pharmacokinetics on ZSP1601, and the Effect of Food on ZSP1601 Pharmacokinetics

Nonalcoholic Steatohepatitis (NASH)

China
Bayer
Amgen

Completed

Study to Determine the Safety, Maximum Tolerated Dose, Pharmacokinetics of Sorafenib (BAY43-9006)

Carcinoma

United States
Tobira Therapeutics, Inc.

Completed

A Proof of Concept Study to Evaluate the Antiviral Activity, Safety, and Pharmacokinetics of the CCR5 Antagonist TBR 652 in HIV 1-Infected, Antiretroviral Treatment-Experienced, CCR5 Antagonist-Naïve Patients

HIV-1 Infection
Eisai Co., Ltd.

Completed

A Double-Blind Study of E5555 in Japanese Subjects With Coronary Artery Disease

Coronary Artery Disease

Japan
AstraZeneca

Completed

PET Study in Parkinson's Disease Patients

Parkinson's Disease

Sweden
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-40411813 in Male and Female Elderly Patients

Healthy

Belgium
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Efficacy and Safety of SP2086 as Monotherapy in Patients With Type 2 Diabetes

Type 2 Diabetes

China
Warner Chilcott

Completed

Treatment of Erectile Dysfunction - Long Term Safety and Efficacy

Erectile Dysfunction

United States
Oxford Cannabinoid Technologies Holdings PLC
Simbec-Orion Group

Completed

Single Ascending Oral Dose Study to Investigate the Effects of OCT461201 in Healthy Volunteers

Healthy

United Kingdom
Galapagos NV

Completed

A Study to Evaluate Multiple Doses of GLPG2222 in Adult Subjects With Cystic Fibrosis

Cystic Fibrosis

Spain, United Kingdom, United States, Netherlands, Belgium, Serbia
GlaxoSmithKline

Terminated

An Adaptive Phase II Study to Evaluate the Efficacy, Pharmacodynamics, Safety and Tolerability of GSK2586184

Systemic Lupus Erythematosus

Estonia, Germany, South Africa, Peru, Sweden, France, Korea, Republic of, Hong Kong, Spain, Romania, Czechia, Argentina, Chile, Hungary, Greece, Poland
ViiV Healthcare
GlaxoSmithKline

Completed

ING200336, Pharmacokinetic and Safety Study in Pregnant Women With Human Immuno Virus Infection

HIV Infections | Arthralgia | Infection, Human Immunodeficiency Virus

Spain, Russian Federation
Merck Sharp & Dohme LLC

Completed

A Study to Demonstrate the Bioequivalence of Sitagliptin/Metformin Combination Tablets and Co-administration of Sitagliptin and Metformin as Individual Tablets (0431A-095)

Type 2 Diabetes
Merck Sharp & Dohme LLC

Completed

Elbasvir (EBR)/Grazoprevir (GZR) in Pediatric Participants With Chronic Hepatitis C Infection (MK-5172-079)

HCV Infection

United States, Germany, Poland, Sweden
Janssen Pharmaceutical K.K.

Completed

An Efficacy and Safety of CNTO 1959 (Guselkumab) in Participants With Moderate to Severe Plaque-type Psoriasis

Psoriasis

Japan
Vanda Pharmaceuticals

Completed

VEC-162 Study in Healthy Adult Volunteers in a Model of Insomnia

Insomnia

United States
Janssen Pharmaceutical K.K.

Completed

A Safety, Tolerability and Pharmacokinetics Study of JNJ-54861911 in Healthy Japanese Male Participants

Healthy

Japan
Kissei Pharmaceutical Co., Ltd.

Completed

Extension to Study on Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain (EDELWEISS 6)

Endometriosis

United States, Austria, Bulgaria, Czechia, France, Poland, Romania, Spain, Ukraine
Kissei Pharmaceutical Co., Ltd.

Terminated

Extension to Study on Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain (EDELWEISS 5)

Endometriosis

United States, Canada, Puerto Rico
CymaBay Therapeutics, Inc.

Completed

Study to Evaluate the Effects of MBX-8025 in Patients With HoFH

Homozygous Familial Hypercholesterolemia

Canada, France, Netherlands, Norway
Kissei Pharmaceutical Co., Ltd.

Completed

Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain.

Endometriosis

United States, Austria, Bulgaria, Czechia, France, Poland, Romania, Spain, Ukraine, Hungary
ObsEva SA

Terminated

A Phase 3 Study to Confirm the Efficacy and Safety of Linzagolix to Treat Endometriosis-associated Pain

Endometriosis

United States, Canada, Puerto Rico
The Lymphoma Academic Research Organisation
Institute of Cancer Research, United Kingdom

Recruiting

Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell Lymphoma

Mantle Cell Lymphoma

France, United Kingdom, Belgium
Boehringer Ingelheim

Completed

Relative Bioavailability of Different Formulations of BI 671800 in Healthy Male and Female Volunteers

Healthy
Legacy Health System

Unknown

The Use of Pycnogenol® to Alleviate Menopausal Symptoms Induced or Increased by Breast and Gynecological Cancer Treatments

Menopause | Climacteric; Menorrhagia, Menopausal

United States
Procter and Gamble

Completed

Efficacy and Safety of PG-530742 in the Treatment of Mild to Moderate Knee Osteoarthritis

Osteoarthritis, Knee

Hungary, United Kingdom
New York State Psychiatric Institute
National Institute on Drug Abuse (NIDA)

Withdrawn

NT-814: Evaluation of Its Ability to Alter the Abuse Liability of Oxycodone in an Exploratory Clinical Study (NT-814)

Opioid Use Disorder

United States
Idorsia Pharmaceuticals Ltd.

Completed

Study to Investigate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of ACT-389949

Healthy Subjects

Netherlands

3

Subscribe